Proton pump inhibitors relabeling for cancer risk not warranted; long-term studies recommended.
Executive Summary
PROTON PUMP INHIBITOR RELABELING FOR CANCER RISK NOT WARRANTED, FDA's Gastrointestinal Drugs Advisory Committee concluded Nov. 5. "In the presence of [Helicobacter pylori] infection," data do not "demonstrate that long-term antisecretory drug treatment increases the prevalence of atrophic gastritis, the prevalence of intestinal metaplasia, or the risk of developing gastric adenocarcinoma," the committee said.